(e,e,e,e)-squalene

(e,e,e,e)-squalene is a lipid of Fatty Acyls (FA) class. (e,e,e,e)-squalene is associated with abnormalities such as Hypercholesterolemia and Cataract. The involved functions are known as Process, metaplastic cell transformation, Protein Overexpression, Anabolism and Biosynthetic Pathways. (e,e,e,e)-squalene often locates in Membrane, Protoplasm, Plasma membrane, Tissue membrane and Back. The associated genes with (e,e,e,e)-squalene are Genome, IMPACT gene, GAPDH gene, GTF2I gene and Chromatin. The related lipids are Membrane Lipids, cycloartenol, Sterols, Fatty Acids and Nonesterified Fatty Acids.

Cross Reference

Introduction

To understand associated biological information of (e,e,e,e)-squalene, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with (e,e,e,e)-squalene?

(e,e,e,e)-squalene is suspected in Hypercholesterolemia, Cataract and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with (e,e,e,e)-squalene

MeSH term MeSH ID Detail
Acne Vulgaris D000152 35 associated lipids
Adenocarcinoma D000230 166 associated lipids
Alopecia Areata D000506 6 associated lipids
Alzheimer Disease D000544 76 associated lipids
Olfaction Disorders D000857 17 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Body Weight D001835 333 associated lipids
Brain Diseases D001927 27 associated lipids
Per page 10 20 50 100 | Total 84

PubChem Associated disorders and diseases

What pathways are associated with (e,e,e,e)-squalene

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with (e,e,e,e)-squalene?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with (e,e,e,e)-squalene?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with (e,e,e,e)-squalene?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with (e,e,e,e)-squalene

Download all related citations
Per page 10 20 50 100 | Total 1766
Authors Title Published Journal PubMed Link
El Sahly H MF59™ as a vaccine adjuvant: a review of safety and immunogenicity. 2010 Expert Rev Vaccines pmid:20923265
Waddington C et al. Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age. 2010 Health Technol Assess pmid:20923610
Iannitti T and Palmieri B An update on the therapeutic role of alkylglycerols. 2010 Mar Drugs pmid:20948908
Michael-Jubeli R et al. High-temperature gas chromatography-mass spectrometry for skin surface lipids profiling. 2011 J. Lipid Res. pmid:20952798
Esposito S et al. An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to paediatric kidney transplant recipients. 2011 Nephrol. Dial. Transplant. pmid:20974645
De Luca C and Valacchi G Surface lipids as multifunctional mediators of skin responses to environmental stimuli. 2010 Mediators Inflamm. pmid:20981292
Madhun AS et al. An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. 2010 Vaccine pmid:21034828
Packwood DM and Phillips LF A stochastic, local mode study of neon-liquid surface collision dynamics. 2011 Phys Chem Chem Phys pmid:21042647
Bate J et al. Immunogenicity of pandemic (H1N1) 2009 vaccine in children with cancer in the United Kingdom. 2010 Clin. Infect. Dis. pmid:21067352
Smentek L and Hess BA Compelling computational evidence for the concerted cyclization of the ABC rings of hopene from protonated squalene. 2010 J. Am. Chem. Soc. pmid:21080653
Bertolino A et al. Polyisoprenoid amphiphilic compounds as inhibitors of squalene synthesis and other microsomal enzymes. 1978 Biochim. Biophys. Acta pmid:210830
Lin FY et al. Mechanism of action and inhibition of dehydrosqualene synthase. 2010 Proc. Natl. Acad. Sci. U.S.A. pmid:21098670
Ali NA et al. Essential oil composition of leaves of Stachys yemenensis obtained by supercritical COâ‚‚. 2010 Nat. Prod. Res. pmid:21104527
Walker WT and Faust SN Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine. 2010 Expert Rev Vaccines pmid:21105775
Wu J et al. Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice. 2011 Arch. Virol. pmid:21110049
Kato S et al. Clinical evaluation of fullerene-C60 dissolved in squalane for anti-wrinkle cosmetics. 2010 J Nanosci Nanotechnol pmid:21137794
Andrews N et al. Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. 2011 J. Infect. Dis. pmid:21148494
Kajaste-Rudnitski A et al. Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals. 2011 AIDS pmid:21150561
Javelle E et al. Delayed focal lipoatrophy after AS03-adjuvanted influenza A (H1N1) 2009 vaccine. 2011 Vaccine pmid:21172376
Montana M et al. Safety review: squalene and thimerosal in vaccines. 2010 Nov-Dec Therapie pmid:21176760
Montagnani S et al. Autoimmune hemolytic anemia following MF59-adjuvanted influenza vaccine administration: a report of two cases. 2011 Ann Pharmacother pmid:21189364
Esposito S et al. Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents. 2011 Vaccine pmid:21199699
van den Brand JM et al. Efficacy of vaccination with different combinations of MF59-adjuvanted and nonadjuvanted seasonal and pandemic influenza vaccines against pandemic H1N1 (2009) influenza virus infection in ferrets. 2011 J. Virol. pmid:21209108
Calabro S et al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. 2011 Vaccine pmid:21215831
Sarpietro MG et al. Synthesis of n-squalenoyl cytarabine and evaluation of its affinity with phospholipid bilayers and monolayers. 2011 Int J Pharm pmid:21219999
Alghisi F et al. Immunogenicity and safety profile of the monovalent A/H1N1 MF59-adjuvanted vaccine in patients affected by cystic fibrosis. 2011 Thorax pmid:21228426
Durando P et al. Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine. 2011 Jan-Feb Hum Vaccin pmid:21245655
Schellenberger MT et al. Evaluation of adjuvants for a candidate conjugate vaccine against benzo[a]pyrene. 2011 Jan-Feb Hum Vaccin pmid:21245662
Brasser AJ et al. Presence of wax esters and squalene in human saliva. 2011 Arch. Oral Biol. pmid:21247555
Morel S et al. Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. 2011 Vaccine pmid:21256188
Lama-Muñoz A et al. New hydrothermal treatment of alperujo enhances the content of bioactive minor components in crude pomace olive oil. 2011 J. Agric. Food Chem. pmid:21265536
Ellebedy AH et al. Inflammasome-independent role of the apoptosis-associated speck-like protein containing CARD (ASC) in the adjuvant effect of MF59. 2011 Proc. Natl. Acad. Sci. U.S.A. pmid:21270336
Decaro N et al. Immunogenicity and protective efficacy in dogs of an MF59â„¢-adjuvanted vaccine against recombinant canine/porcine coronavirus. 2011 Vaccine pmid:21272607
Arias JL et al. Squalene based nanocomposites: a new platform for the design of multifunctional pharmaceutical theragnostics. 2011 ACS Nano pmid:21275408
Arguedas A et al. Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age. 2011 Hum Vaccin pmid:21285531
Manuel O et al. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. 2011 Clin. Infect. Dis. pmid:21288852
Beran J et al. A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses. 2010 Clin Ther pmid:21316535
Fabbiani M et al. Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients. 2011 Vaccine pmid:21349364
Gill S et al. Cholesterol-dependent degradation of squalene monooxygenase, a control point in cholesterol synthesis beyond HMG-CoA reductase. 2011 Cell Metab. pmid:21356516
Lens M and Podesta Marty MH Assessment of the kinetics of the antioxidative capacity of topical antioxidants. 2011 J Drugs Dermatol pmid:21369642
Cristiani C et al. Safety of MF-59 adjuvanted vaccine for pandemic influenza: results of the vaccination campaign in an Italian health district. 2011 Vaccine pmid:21396903
Parretta E et al. Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination. 2011 Vaccine pmid:21406267
Ambike A et al. Interaction of self-assembled squalenoyl gemcitabine nanoparticles with phospholipid-cholesterol monolayers mimicking a biomembrane. 2011 Langmuir pmid:21413743
Sun Y et al. A reproducible in-vivo model of lymphatic malformation in rats. 2011 J. Comp. Pathol. pmid:21419420
Meier S et al. Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children. 2011 Vaccine pmid:21419775
Réjiba S et al. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer. 2011 Nanomedicine pmid:21419876
Banzhoff A et al. Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations. 2011 Hum Vaccin pmid:21422814
Tabache F et al. Acute polyarthritis after influenza A (H1N1) immunization. 2011 Joint Bone Spine pmid:21444232
Liu CL et al. The direct observation of secondary radical chain chemistry in the heterogeneous reaction of chlorine atoms with submicron squalane droplets. 2011 Phys Chem Chem Phys pmid:21455529
Esposito S et al. Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months. 2011 Pediatrics pmid:21464195
Gao J et al. Laser-induced acoustic desorption/atmospheric pressure chemical ionization mass spectrometry. 2011 J. Am. Soc. Mass Spectrom. pmid:21472571
Weschler CJ et al. Squalene and cholesterol in dust from danish homes and daycare centers. 2011 Environ. Sci. Technol. pmid:21476540
Cauda V et al. "Liquid-phase calcination" of colloidal mesoporous silica nanoparticles in high-boiling solvents. 2011 J. Am. Chem. Soc. pmid:21480591
Griffiths PD et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. 2011 Lancet pmid:21481708
Vidal C et al. Seborrheic dermatitis and HIV infection. Qualitative analysis of skin surface lipids in men seropositive and seronegative for HIV. 1990 J. Am. Acad. Dermatol. pmid:2148754
Stone HD and Xie ZX Efficacy of experimental Newcastle disease water-in-oil oil-emulsion vaccines formulated from squalane and squalene. 1990 Oct-Dec Avian Dis. pmid:2149264
Inagaki YS et al. Investigation of the potential for triterpene synthesis in rice through genome mining and metabolic engineering. 2011 New Phytol. pmid:21501172
Garcia-Sicilia J et al. Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents. 2011 Vaccine pmid:21504774
Yockel S and Schatz GC Dynamic QM/MM: a hybrid approach to simulating gas-liquid interactions. 2012 Top Curr Chem pmid:21506003
O'Hagan DT et al. MF59 adjuvant: the best insurance against influenza strain diversity. 2011 Expert Rev Vaccines pmid:21506643
Esposito S et al. Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in children and adolescents with Williams or Cornelia De Lange syndrome. 2011 Hum Vaccin pmid:21508673
Ačimovič J et al. Circadian rhythm of cholesterol synthesis in mouse liver: a statistical analysis of the post-squalene metabolites in wild-type and Crem-knock-out mice. 2011 Biochem. Biophys. Res. Commun. pmid:21531203
Siedenburg G and Jendrossek D Squalene-hopene cyclases. 2011 Appl. Environ. Microbiol. pmid:21531832
Tsai TF et al. Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy. 2011 Scand. J. Infect. Dis. pmid:21534891
Kozlov VG and Viktorova EG [Evaluation of the efficiency and reactogenicity of emulsion-based adjuvant systems in the manufacture of polyclonal enteroviral diagnostic sera]. 2011 Mar-Apr Vopr. Virusol. pmid:21545042
Zhang LW et al. Oil components modulate the skin delivery of 5-aminolevulinic acid and its ester prodrug from oil-in-water and water-in-oil nanoemulsions. 2011 Int J Nanomedicine pmid:21556344
Raouane M et al. Synthesis, characterization, and in vivo delivery of siRNA-squalene nanoparticles targeting fusion oncogene in papillary thyroid carcinoma. 2011 J. Med. Chem. pmid:21561161
Nowosielski M and Hoffmann M Do the substituent effects affect conformational freedom of squalene in hopene biosynthesis? 2011 J Mol Model pmid:21562825
Lopez P et al. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults. 2011 J. Infect. Dis. pmid:21606530
Cen-Pacheco F et al. Cytotoxic oxasqualenoids from the red alga Laurencia viridis. 2011 Eur J Med Chem pmid:21616566
Launay O et al. Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. 2011 J. Infect. Dis. pmid:21628666
Khurana S et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. 2011 Sci Transl Med pmid:21632986
Hirayama C et al. Serum cholesterol and squalene in hepatocellular carcinoma. 1979 Clin. Chim. Acta pmid:216506
Seubert A et al. Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. 2011 Proc. Natl. Acad. Sci. U.S.A. pmid:21690334
Piccialli V et al. Isolation of a bis-iodurated tetra-THF as a trace product from the oxidation of squalene with RuOâ‚„ and its double ring expansion to a novel bis-THF-bis-THP compound. 2011 Molecules pmid:21709619
Iannazzo S Pharmacoeconomic evaluation of the MF59--adjuvanted influenza vaccine in the elderly population in Italy. 2011 J Prev Med Hyg pmid:21710816
Cheong HJ et al. Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine. 2011 Clin. Vaccine Immunol. pmid:21715575
Brito LA et al. An alternative renewable source of squalene for use in emulsion adjuvants. 2011 Vaccine pmid:21723355
Okike IO et al. The immunogenicity of a novel A (H1N1) vaccine in HIV-infected children. 2011 Vaccine pmid:21742005
Niehaus TD et al. Identification of unique mechanisms for triterpene biosynthesis in Botryococcus braunii. 2011 Proc. Natl. Acad. Sci. U.S.A. pmid:21746901
Mackay D and Jones PJ Evaluation of methods for the determination of cholesterol absorption and synthesis in humans. 2011 Atherosclerosis pmid:21763652
Jawaid AM et al. Shape-controlled colloidal synthesis of rock-salt lead selenide nanocrystals. 2011 ACS Nano pmid:21770427
Narayan BH et al. Modulation of doxorubicin-induced genotoxicity by squalene in Balb/c mice. 2010 Food Funct pmid:21776469
Kowert BA and Watson MB Diffusion of organic solutes in squalane. 2011 J Phys Chem B pmid:21780767
Bildstein L et al. Interaction of an amphiphilic squalenoyl prodrug of gemcitabine with cellular membranes. 2011 Eur J Pharm Biopharm pmid:21784150
Viganò A et al. Long-term immunogenicity after one and two doses of a monovalent MF59-adjuvanted A/H1N1 Influenza virus vaccine coadministered with the seasonal 2009-2010 nonadjuvanted Influenza virus vaccine in HIV-infected children, adolescents, and young adults in a randomized controlled trial. 2011 Clin. Vaccine Immunol. pmid:21795458
Huijskens E et al. Immunogenicity, boostability, and sustainability of the immune response after vaccination against Influenza A virus (H1N1) 2009 in a healthy population. 2011 Clin. Vaccine Immunol. pmid:21795459
Pollard AJ and Hill AV Antibody repertoire: embracing diversity. 2011 Sci Transl Med pmid:21795586
Oliaro-Bosso S et al. Characterization of the channel constriction allowing the access of the substrate to the active site of yeast oxidosqualene cyclase. 2011 PLoS ONE pmid:21811565
Desmaële D et al. Squalenoylation: a generic platform for nanoparticular drug delivery. 2012 J Control Release pmid:21840355
Andrews NJ et al. Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines. 2011 Vaccine pmid:21875635
Meyer K et al. A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infection. 2011 PLoS ONE pmid:21887300
Della Cioppa G et al. Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study. 2011 Vaccine pmid:21906647
Fox CB et al. Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. 2011 Vaccine pmid:21906648
Soto G et al. Acetoacetyl-CoA thiolase regulates the mevalonate pathway during abiotic stress adaptation. 2011 J. Exp. Bot. pmid:21908473
Zuccotti GV et al. Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus. 2011 Diabet. Med. pmid:21916971
Broeders NE et al. Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort study. 2011 Clin J Am Soc Nephrol pmid:21921153
Achiraman S et al. Increased squalene concentrations in the clitoral gland during the estrous cycle in rats: an estrus-indicating scent mark? 2011 Theriogenology pmid:21924481
Precioso AR et al. A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems. 2011 Vaccine pmid:21945258
Pariani E et al. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy. 2011 Vaccine pmid:21974995